KIAA0494 Inhibitors
KIAA0494 inhibitors pertain to a class of chemical compounds designed to specifically interact with the protein encoded by the KIAA0494 gene. This gene is known to play a role in various cellular processes, although its full biological function is not completely understood. The inhibitors targeting this protein are the result of intricate molecular design and synthesis processes aimed at modulating the activity of the protein. By binding to the active site or other regulatory regions of the KIAA0494 protein, these inhibitors can affect the protein's function. The design of such inhibitors often involves the identification of key amino acid residues within the protein that are critical for its activity. Once identified, chemical compounds can be engineered to interact with these residues, either by blocking the active site directly or by altering the protein's conformation in a way that reduces its activity.
The development of KIAA0494 inhibitors typically involves extensive research into the protein's structure and function. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy may be employed to gain a three-dimensional understanding of the protein at atomic resolution. With this structural information, chemists can design molecules that have the right shape, charge distribution, and chemical functionality to interact with the protein. Computational methods, including molecular modeling and virtual screening, are often utilized to predict how potential inhibitors might interact with the protein and to optimize their structures before synthesis. Once synthesized, these compounds are usually subjected to a battery of biochemical assays to determine their efficacy in inhibiting the KIAA0494 protein. The process of inhibitor optimization is iterative, with initial hits undergoing refinement to improve their potency and selectivity for the target protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective and potent inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of the extracellular signal-regulated kinase (ERK) pathway. Inhibition of MEK by PD 98059 will prevent the phosphorylation and activation of ERK, which may be necessary for the functional activity of KIAA0494, leading to its indirect inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule that functions as an inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling is crucial for many cellular processes including growth and survival. Inhibition of PI3K by LY294002 could disrupt downstream signaling pathways, potentially leading to a decrease in KIAA0494 activity if KIAA0494 is reliant on PI3K-mediated signaling for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). The p38 MAPK signaling pathway is involved in inflammatory responses and stress-induced cellular events. Inhibition of p38 MAPK by SB203580 could lead to reduced KIAA0494 activity if KIAA0494 function is modulated by stress or inflammation-related signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, which are upstream activators of the ERK pathway. By inhibiting MEKs, U0126 prevents the activation of ERK, potentially reducing the activity of KIAA0494 if it is regulated by the MEK/ERK signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), which is a key regulator of cell growth and metabolism. By inhibiting mTOR, Rapamycin could lead to a decrease in KIAA0494 activity if KIAA0494 is involved in mTOR-controlled signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK is involved in regulating cytoskeletal dynamics. Inhibition of ROCK signaling by Y-27632 could impact KIAA0494 if its function is associated with cytoskeletal rearrangements or cell motility processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor that targets c-Jun N-terminal kinase (JNK). JNK signaling is implicated in the control of apoptosis and cellular differentiation. Inhibition of JNK by SP600125 may decrease KIAA0494 activity if KIAA0494 is part of pathways regulated by JNK activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By blocking EGFR signaling, Gefitinib can disrupt downstream pathways that might be essential for KIAA0494 activity, such as those involved in cell proliferation or survival. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective inhibitor of the mutant forms of EGFR that are resistant to first-generation inhibitors. It disrupts EGFR signaling pathways, potentially decreasing KIAA0494 activity if KIAA0494 is involved in the same pathways as EGFR, particularly those variants that are typically resistant to other forms of inhibition. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
AZD0530 is a selective inhibitor of Src family kinases, which play roles in various signaling pathways including cell adhesion, growth, and migration. Inhibition of Src kinases by AZD0530 could lead to reduced activity of KIAA0494 if it is regulated by Src-mediated signaling. | ||||||